Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 12;385(7):585-594.
doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Jamie Lopez Bernal  1 , Nick Andrews  1 , Charlotte Gower  1 , Eileen Gallagher  1 , Ruth Simmons  1 , Simon Thelwall  1 , Julia Stowe  1 , Elise Tessier  1 , Natalie Groves  1 , Gavin Dabrera  1 , Richard Myers  1 , Colin N J Campbell  1 , Gayatri Amirthalingam  1 , Matt Edmunds  1 , Maria Zambon  1 , Kevin E Brown  1 , Susan Hopkins  1 , Meera Chand  1 , Mary Ramsay  1
Affiliations

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Jamie Lopez Bernal et al. N Engl J Med. .

Erratum in

Abstract

Background: The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the globe, including a notable increase in cases in the United Kingdom. The effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines against this variant has been unclear.

Methods: We used a test-negative case-control design to estimate the effectiveness of vaccination against symptomatic disease caused by the delta variant or the predominant strain (B.1.1.7, or alpha variant) over the period that the delta variant began circulating. Variants were identified with the use of sequencing and on the basis of the spike (S) gene status. Data on all symptomatic sequenced cases of Covid-19 in England were used to estimate the proportion of cases with either variant according to the patients' vaccination status.

Results: Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) was notably lower among persons with the delta variant (30.7%; 95% confidence interval [CI], 25.2 to 35.7) than among those with the alpha variant (48.7%; 95% CI, 45.5 to 51.7); the results were similar for both vaccines. With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among persons with the alpha variant and 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant. With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among persons with the alpha variant and 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant.

Conclusions: Only modest differences in vaccine effectiveness were noted with the delta variant as compared with the alpha variant after the receipt of two vaccine doses. Absolute differences in vaccine effectiveness were more marked after the receipt of the first dose. This finding would support efforts to maximize vaccine uptake with two doses among vulnerable populations. (Funded by Public Health England.).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Vaccine Effectiveness against the Alpha and Delta Variants, According to Dose and Vaccine Type.
Shown is the effectiveness of one dose and two doses of the BNT162b2 and ChAdOx1 nCoV-19 vaccines, or either vaccine (“any”), against symptomatic disease with the B.1.1.7 (alpha) or B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2. 𝙸 bars indicate 95% confidence intervals.
See this image and copyright information in PMC

Comment in

References

    1. European Centre for Disease Prevention and Control. Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. May 11, 2021. (https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emerge...).
    1. Rubin EJ, Baden LR, Udwadia ZF, Morrissey S. India’s Covid-19 crisis. N Engl J Med 2021;384(18):e84-e84. - PubMed
    1. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Chall 2017;1:33-46. - PMC - PubMed
    1. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 11. May 13, 2021. (https://assets.publishing.service.gov.uk/government/uploads/system/uploa...).
    1. Joint Committee on Vaccination and Immunisation. Priority groups for coronavirus (COVID-19) vaccination: advice from the JCVI, 30 December 2020. London: Department of Health and Social Care, January 6, 2021. (https://www.gov.uk/government/publications/priority-groups-for-coronavir...).

Publication types

Substances